Scholarlink

<p>To evaluate the efficacy and safety of intraventricular (IVT) colistin in combination with intravenous therapy for the treatment of multidrug-resistant (MDR) ventriculitis following neurosurgical procedures, and to determine optimal treatment duration and outcomes in the largest single-centre series to date.&#xa0;This retrospective study analysed 46 patients with culture-proven MDR ventriculitis treated at a tertiary care neurosurgical centre between January 2023 and December 2024. All pathogens had a colistin MIC of <i>≤</i> 2&#xa0;µg/mL. IVT colistin (10&#xa0;mg colistimethate sodium) was administered via external ventricular drain (EVD) for variable durations. Outcomes were compared between patients receiving IVT plus intravenous colistin for ≥ 10 days versus those receiving shorter courses and intravenous colistin alone. The primary outcome was clinical cure; secondary endpoints included infection control timing, mortality, and adverse events.&#xa0;Infection was controlled in 63.6% of cases, with a median time to CSF sterilisation of 7.5 days. Patients receiving IVT and intravenous colistin for ≥ 10 days had significantly higher infection control rates (94% vs. 37%, <i>p</i> = 0.001), lower overall mortality (45% vs. 75%, <i>p</i> = 0.013), and reduced infection-attributable mortality (18.8% vs. 56.3%, <i>p</i> = 0.028) when compared to combined treatment given for less than 10 days. Combined treatment also had better infection control when compared with those that received only intravenous colistin (94% vs. 58%, <i>p</i> = 0.024). The most frequently isolated organism was <i>Acinetobacter baumannii</i> (50%). Adverse effects were limited to acute kidney injury in 4 patients (8.7%), with no neurotoxicity reported.&#xa0;IVT colistin appears to be a safe and effective adjunct to systemic therapy in MDR ventriculitis, particularly when administered for ≥ 10 days. It significantly improves infection control and may reduce infection-related mortality. Given its low neurotoxicity and favourable outcomes in appropriately selected patients, IVT colistin should be considered a cornerstone in managing MDR gram-negative ventriculitis. Prospective multicenter studies are needed to establish standardised treatment protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intraventricular colistin for multidrug-resistant ventriculitis: the final therapeutic option?

  • 期刊论文

  • 发表日期：

    2026年2月21日

查看全文
  • Mohammed Nadeem,
  • Subhas Konar,
  • T Vidhya,
  • U Shashank,
  • Ravi Bhutra,
  • Abhijit Goyal-Honavar,
  • R Amrutha Varshini,
  • H B Veenakumari,
  • Dhaval Shukla

摘要

To evaluate the efficacy and safety of intraventricular (IVT) colistin in combination with intravenous therapy for the treatment of multidrug-resistant (MDR) ventriculitis following neurosurgical procedures, and to determine optimal treatment duration and outcomes in the largest single-centre series to date. This retrospective study analysed 46 patients with culture-proven MDR ventriculitis treated at a tertiary care neurosurgical centre between January 2023 and December 2024. All pathogens had a colistin MIC of ≤ 2 µg/mL. IVT colistin (10 mg colistimethate sodium) was administered via external ventricular drain (EVD) for variable durations. Outcomes were compared between patients receiving IVT plus intravenous colistin for ≥ 10 days versus those receiving shorter courses and intravenous colistin alone. The primary outcome was clinical cure; secondary endpoints included infection control timing, mortality, and adverse events. Infection was controlled in 63.6% of cases, with a median time to CSF sterilisation of 7.5 days. Patients receiving IVT and intravenous colistin for ≥ 10 days had significantly higher infection control rates (94% vs. 37%, p = 0.001), lower overall mortality (45% vs. 75%, p = 0.013), and reduced infection-attributable mortality (18.8% vs. 56.3%, p = 0.028) when compared to combined treatment given for less than 10 days. Combined treatment also had better infection control when compared with those that received only intravenous colistin (94% vs. 58%, p = 0.024). The most frequently isolated organism was Acinetobacter baumannii (50%). Adverse effects were limited to acute kidney injury in 4 patients (8.7%), with no neurotoxicity reported. IVT colistin appears to be a safe and effective adjunct to systemic therapy in MDR ventriculitis, particularly when administered for ≥ 10 days. It significantly improves infection control and may reduce infection-related mortality. Given its low neurotoxicity and favourable outcomes in appropriately selected patients, IVT colistin should be considered a cornerstone in managing MDR gram-negative ventriculitis. Prospective multicenter studies are needed to establish standardised treatment protocols.